Related references
Note: Only part of the references are listed.Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations
Rupam Borgohain et al.
MOVEMENT DISORDERS (2014)
Two-Year, Randomized, Controlled Study of Safinamide as Add-on to Levodopa in Mid to Late Parkinson's Disease
Rupam Borgohain et al.
MOVEMENT DISORDERS (2014)
Non-dopaminergic Treatments for Motor Control in Parkinson's Disease
Susan H. Fox
DRUGS (2013)
Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson's disease
A. H. V. Schapira et al.
EUROPEAN JOURNAL OF NEUROLOGY (2013)
Safinamide reduces dyskinesias and prolongs L-DOPA antiparkinsonian effect in parkinsonian monkeys
Laurent Gregoire et al.
PARKINSONISM & RELATED DISORDERS (2013)
Disposition and Metabolism of Safinamide, a Novel Drug for Parkinson's Disease, in Healthy Male Volunteers
Chiara Leuratti et al.
PHARMACOLOGY (2013)
Tremorolytic effects of safinamide in animal models of drug-induced parkinsonian tremor
Samantha Podurgiel et al.
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR (2013)
Effects of ketoconazole treatment on the pharmacokinetics of safinamide and its plasma metabolites in healthy adult subjects
Sonja Kroesser et al.
BIOPHARMACEUTICS & DRUG DISPOSITION (2012)
A Randomized, Double-Blind, Placebo-Controlled Trial of Safinamide as Add-on Therapy in Early Parkinson's Disease Patients
Fabrizio Stocchi et al.
MOVEMENT DISORDERS (2012)
Monoamine Oxidase B Inhibitors for the Treatment of Parkinson's Disease A Review of Symptomatic and Potential Disease-Modifying Effects
Anthony H. V. Schapira
CNS DRUGS (2011)
Pressor response to oral tyramine during co-administration with safinamide in healthy volunteers
Andrea Francesco Daniele Di Stefano et al.
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY (2011)
Safinamide - From molecular targets to a new anti-Parkinson drug
C. Caccia et al.
NEUROLOGY (2006)
Improvement of motor function in early Parkinson disease by safinamide
F Stocchi et al.
NEUROLOGY (2004)
Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity
A Marzo et al.
PHARMACOLOGICAL RESEARCH (2004)
Pressor response to intravenous tyramine in healthy subjects after safinamide, a novel neuroprotectant with selective, reversible monoamine oxidase B inhibition
C Cattaneo et al.
CLINICAL NEUROPHARMACOLOGY (2003)
Share Paper
